# Hannah Tapsell Chapman

> Hannah Tapsell Chapman is a seed investor at Mercia’s EIS funds backing Biotechnology and EdTech. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Mercia’s EIS funds](https://shizune.co/investors/profile/mercia-s-eis-funds)
- Total investments: 6
- Last investment: Feb 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/hannah-tapsell-chapman-4bb07964/

Hannah Tapsell Chapman is a seed investor at Mercia’s EIS funds focused on Biotechnology and EdTech. Hannah Tapsell Chapman is the Investment Manager at Mercia Asset Management PLC.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 33% |
| EdTech | 1 | 17% |
| Genetics | 1 | 17% |
| Training | 1 | 17% |
| E-Learning | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 50% |
| Venture - Series Unknown | 2 | 33% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NuVision | NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $6.5M | Venture - Series Unknown | Feb 05, 2026 |  |
| Forge Genetics | Forge Genetics is a startup with proprietary Forge Editing technology, bypassing CRISPR patents for precision gene-editing services. | $2.7M | Seed | Oct 01, 2025 |  |
| Graide | Graide is a feedback platform that provides insight to learn and avoid feedback. | $2.1M | Venture - Series Unknown | Feb 27, 2024 |  |
| IsomAb | IsomAb evaluate and develop isoform specific antibodies to treat disease. | $9.5M | Seed | Feb 20, 2024 |  |
| ImmuONE | ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. |  |  | Oct 25, 2023 |  |
| ImmuONE | ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. | $2.4M | Seed | Oct 25, 2023 |  |

6 of 6 investments shown.

## Co-investors
- [MEIF Proof-of-Concept & Early Stage Fund](https://shizune.co/investors/profile/meif-proof-of-concept-early-stage-fund) — VC Fund, 3 deals together
- [Pioneer Group](https://shizune.co/investors/profile/pioneer-group-598a) — VC Fund, 3 deals together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 2 deals together
- [SCVC](https://shizune.co/investors/profile/science-creates-ventures) — VC Fund, 2 deals together
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund, 1 deal together
- [University of Nottingham](https://shizune.co/investors/profile/university-of-nottingham) — VC Fund, 1 deal together

## About Mercia’s EIS funds

VC Fund

Mercia’s EIS funds

1 contacts available at Mercia’s EIS funds.

| Name | Title | Profile |
| --- | --- | --- |
| Hannah Tapsell Chapman | Venture Capital Investor | https://shizune.co/investors/profile/hannah-tapsell-chapman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Hannah Tapsell Chapman invest in?

Hannah Tapsell Chapman invests primarily in Biotechnology, EdTech and Genetics startups, most often at Seed and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hannah Tapsell Chapman last invest?

The most recent investment recorded for Hannah Tapsell Chapman closed in Feb 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co